[ad_1]
Shorten URL
https://cdntr1.img.sputniknews.com/img/104178/78/1041787808_0:0:1280:721_1200x675_80_0_0_697ad59d68b0a65c002675f9a44aa2ea.jpg
Sputnik Turkey
https://cdntr2.img.sputniknews.com/i/logo.png
Sputnik
https://cdntr2.img.sputniknews.com/i/logo.png
https://tr.sputniknews.com/turkiye/202005141042035607-prof-dr-ercument-ovalidan-dornaz-alfa-ile-ilgili-yeni-aciklama/
Coming onto the agenda with his studies against the coronavirus and explaining the name of the active substance Dornaz Alfa. Dr. Ercüment Ovalı made new statements on Twitter.
Professor Dr. Ercüment Ovalı announced that the first clinical and laboratory data from Dornaz Alfa, which reported that they not only melted the membrane causing lung problems, but could also function as antivirals, were published as a preprint.
Professor Dr. Ercüment Ovalı shared information about vaccination studies from his social media account.
Ovalı announced that the animal experiments, which are the first step in the vaccine targeting 2 million doses in the first batch, continue without issue.
Information:
The experiments with animals of primary level of our ace, that we aim at 2 million doses in the first batch, continue without any problem. The goal is to start clinical trials in September.– Ercüment ovalı (@ercumentovali) May 13, 2020
Professor Dr. Ovalı shared his knowledge of “Goal, start clinical trials in September”.
Dornaz Alfa data has been published
Ovalı, in his statement, said: “Our first clinical and laboratory data, which we report that Dornaz Alfa not only melts the membrane causing lung problems, but can also function as an antiviral, were published as preprints.”
Our first clinical and laboratory data, which we report that Dornase Alfa not only dissolves the membrane that causes lung problems, but also works as an antiviral, were published as a preprint.
– Ercüment ovalı (@ercumentovali) May 13, 2020
[ad_2]
